Khiron Life Sciences Corp.
KHRWF
Other OTC0.02
USD
+0.01
- -
Return %
Stock
S&P500
1Y
-94.21
26.53
3Y
-80.38
76.60
5Y
-80.38
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Alvaro Francisco Torres
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Similar Companies
- Business
- Khiron Life Sciences Corp. operates as a vertically integrated medical cannabis and healthcare services company, with its primary focus in Latin America following a strategic re-evaluation of its European presence. The company structures its business across segments including Medical Cannabis Products, Health Services, and Wellbeing Products. It is involved in the production, distribution, and export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis, with a recent shift to outsourcing cultivation and extraction activities in Colombia to emphasize its high-margin clinic operations. Khiron manages an extensive network of health centers and telemedicine platforms under the Zerenia™ brand, which deliver integrated care for various conditions, and previously integrated neurology services through the ILANS brand. Additionally, it develops and markets CBD-infused cosmeceutical items under its Kuida™ brand. Khiron Life Sciences Corp. was established in 2012 and maintains its headquarters in Vancouver, Canada.